Mucopolysaccharidosis Treatment Market Size

Mucopolysaccharidosis Treatment Market size was over USD 11.68 billion in 2024 and is projected to reach USD 31.01 billion by 2037, growing at around 7.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of rapid antigen testing is assessed at USD 12.41 billion. HSCT, also known as bone marrow transplant, involves replacing the patient's faulty bone marrow or stem cells with healthy donor cells that produce the missing enzyme. In addition to these established treatments, ongoing research and development efforts were focused on finding new therapies and improving existing ones. These efforts might include gene therapy, small molecule drugs, and other innovative approaches aimed at addressing the underlying genetic and biochemical factors contributing to MPS.

Mucopolysaccharidosis (MPS) refers to a group of rare genetic disorders known as lysosomal storage disorders. These disorders are characterized by the accumulation of glycosaminoglycans (GAGs) due to the deficiency of specific enzymes required for their breakdown within lysosomes. This leads to a range of symptoms and complications affecting various organs and systems in the body.